IMDX surges 3.5% on FDA submission for transplant test
First kitted dd-cfDNA assay submission marks milestone for kidney transplant rejection testing
Insight Molecular Diagnostics (IMDX) shares surged 3.5% to $4.14 on Wednesday, bucking broader market weakness as the precision diagnostics company submitted its GraftAssureDx test to the U.S. Food and Drug Administration for review. The positive market reaction came despite the company missing quarterly earnings estimates, with investors focusing instead on the strategic significance of becoming the first company to submit a kitted donor-derived cell-free DNA (dd-cfDNA) assay for regulatory approval.
The FDA submission, completed on March 25, marks a critical milestone for IMDX as it advances its kidney transplant rejection testing platform toward commercialization. The GraftAssureDx test quantifies dd-cfDNA, a biomarker used to assess the risk of organ rejection in transplant patients. According to company announcements, the FDA's 150-day review clock has officially begun, with a potential approval decision expected in 2026.
For the fourth quarter ended December 31, 2025, IMDX reported revenue of $1.1 million, easily surpassing analyst expectations of $0.3 million. The strong quarterly performance contributed to full-year revenue of $4.1 million, representing a 116% year-over-year increase from $1.9 million in 2024. The company's trailing twelve-month revenue reached $4.4 million as of September 30, 2025.
However, the company recorded a net loss of $23.0 million, or $0.72 per share, for the quarter, which included $14.6 million in non-cash impairment losses related to its oncology programs. StreetInsider reported that the adjusted loss per share came in at $0.27, missing analyst estimates of a $0.25 loss.
The revenue growth reflects expanding commercial traction for IMDx's diagnostic platform. The company currently operates GraftAssureCore, a laboratory-developed test (LDT) that is reimbursed by the Centers for Medicare and Medicaid Services (CMS). The FDA submission for GraftAssureDx represents the next stage in the company's strategy, converting the technology into an in vitro diagnostic (IVD) kit for broader clinical use.
IMDX has established partnerships with 37 U.S. transplant centers, representing more than 25% of all kidney transplant procedures performed in the United States. In February 2026, the company raised $26 million in financing to support operations through the FDA review process and potential commercialization.
The company has provided Q4 cash burn guidance of approximately $7.5 million per quarter. With 28.7 million shares outstanding and a market capitalization of $114.7 million, IMDX trades at approximately 26 times trailing twelve-month revenue. Analysts maintain an average price target of $8.33, according to market data, suggesting significant upside potential if the FDA submission proceeds successfully.
The market for transplant rejection testing represents a significant commercial opportunity. Industry analysts estimate the total addressable market ranges between $1 billion and $2 billion. A peer-reviewed study published in Transplant International in March 2026 supported the GraftAssure assay's ability to predict kidney transplant rejection, providing additional clinical validation ahead of the FDA review.
The FDA's de novo submission process, which IMDx is pursuing for GraftAssureDx, is designed for novel medical devices that present no reasonable assurance of safety and effectiveness. The 150-day review timeline provides a clear pathway to potential approval, though the agency has the discretion to request additional information or extend the review period.
Institutional investors hold 52.3% of IMDx shares, while insiders own 19.5%. The stock has traded within a 52-week range of $2.33 to $8.51, reflecting high volatility as the company advances its clinical development programs. The shares currently trade above both the 50-day and 200-day moving averages of $5.98 and $4.63, respectively, though the recent pullback from March highs suggests some profit-taking following the FDA submission announcement.
Looking ahead, investors will focus on the FDA review timeline and any requests for additional information from the agency. The company has indicated plans to commercialize the diagnostic technology starting in 2026, assuming regulatory approval, and has initiated a clinical trial planning to enroll 5,000 patients in a real-world evidence registry. The successful development of GraftAssureDx would position IMDx as a first mover in the kitted dd-cfDNA assay market, potentially capturing significant share in the rapidly growing transplant diagnostics sector.